2-((2-Amino-6-oxo-3,6-dihydro-9H-purin-9-yl)methoxy)-3-hydroxypropyl ((benzyloxy)carbonyl)-L-valinate

This compound is typically isolated as a white to off-white amorphous or crystalline powder. Its molecular formula is C22H28N6O7, corresponding to a molecular weight of 488.49. The melting point is not sharply defined, with decomposition often occurring above 180 °C. The calculated density is approximately 1.45 g/cm³ under ambient conditions. It exhibits good solubility in polar aprotic solvents such as dimethyl sulfoxide and dimethylformamide, moderate solubility in methanol and ethanol, and limited solubility in water and chlorinated solvents. The molecule contains multiple hydrogen bond donors and acceptors from the purine base, carbamate, and hydroxyl groups. The benzyloxycarbonyl (Cbz) protecting group is stable under basic conditions but readily cleaved by hydrogenolysis or strong acids. Storage in tightly sealed containers under inert atmosphere at reduced temperature (2–8 °C) is recommended to prevent hydrolysis and decomposition. Contact with strong oxidizing agents, strong acids, and bases should be avoided.

This complex molecule combines a modified guanine nucleobase with a valine-derived amino acid ester through a flexible glycerolipid-like linker. The 9-position of the 2-amino-6-oxopurine (guanine) core bears a substituted glycerol moiety, with one hydroxyl engaged in ether linkage to the purine and the other esterified with a Cbz-protected L-valine residue. This architecture mimics naturally occurring nucleoside-lipid conjugates and prodrugs designed to enhance cellular delivery of nucleoside analogs. The guanine portion provides the potential for base-pairing interactions and recognition by enzymes involved in nucleic acid metabolism. The valine ester introduces both amino acid character and a benzyl carbamate protecting group, which can be removed to reveal a free amine for further functionalization or to modulate pharmacokinetic properties. This multifunctional structure represents a sophisticated building block for constructing antiviral and anticancer nucleoside prodrugs.

Nucleoside Prodrug Development

This compound serves as an advanced intermediate in the synthesis of lipid-modified nucleoside prodrugs designed to bypass resistance mechanisms and improve oral bioavailability. The glycerolipid moiety enhances membrane permeability, while the valine ester can be cleaved by esterases in vivo to release the active nucleoside analog. Such strategies are employed to overcome poor cellular uptake of hydrophilic nucleoside drugs.

Antiviral Research Applications

Modified guanosine derivatives incorporating this scaffold are investigated for activity against DNA and RNA viruses, including hepatitis B and herpesviruses. The amino acid ester can facilitate active transport via peptide transporters, while the purine base acts as a chain terminator after intracellular phosphorylation. Structural variations around the linker and protecting groups enable optimization of antiviral potency and selectivity.

Enzyme-Targeted Drug Delivery

The valine moiety is recognized by amino acid transporters and esterases, enabling targeted delivery to cells expressing these enzymes. After enzymatic cleavage, the released nucleoside analog can be activated by viral or cellular kinases. This approach is explored for enhancing the therapeutic index of nucleoside analogs in cancer and viral infections by concentrating active drug in diseased tissues.

Chemical Biology Probe

The benzyloxycarbonyl group can be replaced with fluorescent tags or affinity handles to create probes for studying nucleoside transport, metabolism, and incorporation into nucleic acids. The glycerol linker provides a versatile attachment point for various reporter groups without disrupting recognition by target enzymes. Such probes are valuable tools for elucidating mechanisms of nucleoside drug action and resistance.